0.258

3.53% 0.0088

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $0.258, with a volume of 1.59M. It is up +3.53% in the last 24 hours and down -51.78% over the past month. Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Previous Close:

$0.2492

Open:

$0.259

24h Volume:

1.59M

Relative Volume:

0.80

Market Cap:

$10.59M

Revenue:

$1.04M

Net Income/Loss:

$-67.50M

P/E Ratio:

-0.1342

EPS:

-1.9222

Net Cash Flow:

$-60.67M

1W Performance:

+3.66%

1M Performance:

-51.78%

6M Performance:

-60.92%

1Y Performance:

-89.38%

1-Day Range:

$0.2471

$0.2639

1-Week Range:

$0.2255

$0.2639

52-Week Range:

$0.198

$5.14

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2026-08-06

Latest SEC Filings

VTGN's Discussions on Twitter

Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTGN Vistagen Therapeutics Inc	0.258	10.59M	1.04M	-67.50M	-60.67M	-1.9222
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-25	Downgrade	Jefferies	Buy → Hold
Dec-17-25	Downgrade	Maxim Group	Buy → Hold
Dec-17-25	Downgrade	Stifel	Buy → Hold
Dec-17-25	Downgrade	William Blair	Outperform → Mkt Perform
Dec-07-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Upgrade	Maxim Group	Hold → Buy
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

Jul 11, 2026

This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits

Jul 11, 2026

Jul 06, 2026

Stifel Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating, Maintains Target Price $1 - Moomoo

Jul 06, 2026

Jul 04, 2026

Penny stock Vistagen keeps regulatory plans alive despite anxiety study miss - MSN

Jul 04, 2026

Jul 03, 2026

Enterprise value to revenue forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN - TradingView

Jul 03, 2026

VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review

Jul 03, 2026

Price to sales forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN - TradingView

Jul 03, 2026

Jul 02, 2026

Vistagen (VTGN) Chief Legal Officer adds 36,818 ESPP shares in Form 4 filing - Stock Titan

Jul 02, 2026

Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com India

Jul 02, 2026

Vistagen (VTGN) CEO adds 36,818 ESPP shares, now holds over 54,000 directly - Stock Titan

Jul 02, 2026

ESPP grant gives Vistagen (NASDAQ: VTGN) CFO 11,712 new shares - Stock Titan

Jul 02, 2026

$VistaGen Therapeutics (VTGN.US)$ - Moomoo

Jul 02, 2026

Jul 01, 2026

VistaGen pivots fasedienol toward long-term anxiety treatment - The Globe and Mail

Jul 01, 2026

Jun 30, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Ther - The National Law Review

Jun 30, 2026

Vistagen’s anxiety disorder drug misses main goal in late-stage trial, shares plummet - Classic Rock 103.5 WIMZ

Jun 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 30, 2026

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss - Benzinga

Jun 30, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Jun 30, 2026